European Medicines Agency starts evaluating use of baricitinib (Olumiant) in hospitalised COVID-19 patients requiring supplemental oxygen

The application is to extend the use of the Janus kinase (JAK)1 and JAK2 inhibitor to include this indication in patients aged ≥10 years. Baricitinib is currently licensed in the UK for the treatment of rheumatoid arthritis and atopic dermatitis.

Source:

European Medicines Agency